Event: SABCS 2024

1:48:22

SABCS 2024: Optimizing early HER2 positive breast cancer treatment

1:02:28

SABCS 2024: The heart of the matter - improving adverse effects

0:00:51

A look at SABCS 2024

0:59:55

SABCS 2024: Rapid Fire 1 session

1:36:00

SABCS 2024: Career development - Patient-driven protocol development

0:29:42

SABCS 2024: The William L McGuire Memorial Lecture

1:33:13

SABCS 2024: View from the Trenches

0:00:42

Updates in liquid biopsy and biomarker development at SABCS 2024

1:08:18

SABCS 2024: Targeting the ER and PI3K pathway - novel drugs and combinations

0:56:07

SABCS 2024: Survivorship - biomarker predictors and other survival associated factors

1:45:47

SABCS 2024: Tumor heterogeneity and evolution

1:47:10

SABCS 2024: FDA special session -- New drug approvals

1:43:21

SABCS 2024: Clinical Workshop - Dose optimization in breast medical oncology

0:01:30

Trials updates at SABCS 2024: EMBER-3 and PATINA

0:01:02

SABCS 2024 highlights: assessing the clinical impact of EMBER-3 and PATINA

0:56:40

SABCS 2024 Roundup: What’s the Latest in Metastatic Breast Cancer (MBC)

0:10:09

🚨 SABCS 2024 EMBER-3 Trial Results | 🚨 Full Press Conference

0:02:09

SABCS 2024 Highlights: PATINA in HR+/HER2+ breast cancer

1:17:18

SABCS 2024: The future of cancer genetics is here

0:01:39

Insights from antibody-drug conjugate research at SABCS 2024

0:02:49

💥SABCS 2024💥 2 Min Update EMBER-3 Results with Slides Imlunestrant with or without Abemaciclib

0:17:35

SABCS 2024 Highlights - EUROPA, TAILORx, PADMA, EMBER-3 with Dr. Jame Abraham

0:07:50

Atezolizumab Stumbles in Triple Negative Breast Cancer Study: SABCS 2024 Results with Charles Geyer

0:02:09

Key takeaways from SABCS 2024: PATINA and other highlights